UTHR Q4 2019 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$311M-18.4% YoY

Gross Profit

$282M90.7% margin

Operating Income

$64M20.4% margin

Net Income

$53M16.9% margin

EPS (Diluted)

$1.20

QoQ Revenue Growth

-22.5%

Cash Flow

Operating Cash Flow

$103M

Free Cash Flow

$78M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$1.1B

Stockholders' Equity

$2.8B

Cash & Equivalents

$738M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$311M	$381M	-18.4%
Gross Profit	$282M	$350M	-19.2%
Operating Income	$64M	$132M	-51.7%
Net Income	$53M	$65M	-19.4%

Revenue Segments

Remodulin

$107M49%

Orenitram

$51M23%

Unituxin

$34M15%

Adcirca

$28M13%

Geographic Segments

U

$295M95%

European Union And Others

$16M5%